Details of the Drug Combination

General Information of Drug Combination (ID: DCCEUHI)

Drug Combination Name

Indazole derivative 5 Valrubicin

Indication

Disease Entry	Status	REF
Anaplastic large cell lymphoma	Investigative	[1]

Component Drugs

Indazole derivative 5 DMM1I8R

Valrubicin DMOYJFK

Small molecular drug

2D MOL

3D MOL

3D MOL is unavailable

High-throughput Screening Result

Testing Cell Line: SR

Zero Interaction Potency (ZIP) Score: 8.14

Bliss Independence Score: 8.89

Loewe Additivity Score: 9.93

LHighest Single Agent (HSA) Score: 10.76

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indazole derivative 5 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
ABL T315I mutant (ABL T315I)	TTZJTWA	ABL1_HUMAN	Inhibitor	[5]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)	TTIV39N	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[5]
------------------------------------------------------------------------------------

Indication(s) of Valrubicin

Disease Entry	ICD 11	Status	REF
Bladder cancer	2C94	Approved	[2]
In situ carcinoma	N.A.	Approved	[3]
Urinary bladder cancer	N.A.	Approved	[3]
Psoriasis vulgaris	EA90	Phase 2	[4]

Valrubicin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Inhibitor	[6]
------------------------------------------------------------------------------------

Valrubicin Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Plasma cell myeloma	DCOPYPK	RPMI-8226	Investigative	[1]
Invasive ductal carcinoma	DCJEEJ2	T-47D	Investigative	[8]
Invasive ductal carcinoma	DCPDFZD	BT-549	Investigative	[8]
Invasive ductal carcinoma	DCYVMRB	HS 578T	Investigative	[8]
Amelanotic melanoma	DCKID3R	MDA-MB-435	Investigative	[9]
Cutaneous melanoma	DCZLM7U	SK-MEL-28	Investigative	[9]
Lung adenocarcinoma	DCVMIGK	HOP-62	Investigative	[9]
Melanoma	DCNWCV0	SK-MEL-2	Investigative	[9]
Melanoma	DCFJY11	MALME-3M	Investigative	[9]
Ovarian serous cystadenocarcinoma	DC96N5K	SK-OV-3	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 DrugCom(s)

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	Valrubicin FDA Label
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
6	Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5.
7	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
8	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
9	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.